Target: Disease-driving RNA transcripts via AAV-mediated delivery
Approach: AAV vectors carrying RNA-targeting payloads (ASO, RNAi, RNA aptamers) to reduce expression of toxic proteins
Therapeutic Area: Alzheimer's Disease, Parkinson's Disease, Amyotrophic Lateral Sclerosis, Frontotemporal Dementia
Score: 77/100
Recombinant AAV vectors provide non-integrating, long-term expression of RNA-targeting payloads in the CNS.[1] Recent advances in capsid engineering have improved CNS tropism and reduced immunogenicity.[2]
Key advantages:
In neurodegeneration, specific genetic drivers can be targeted to reduce toxic protein expression:[4]
AAV delivery addresses the key limitation of traditional ASO approaches (requires repeated intrathecal dosing) while enabling cell-type specific targeting.[5][6]
| Dimension | Score | Rationale |
|---|---|---|
| Novelty | 8 | First-in-class AAV+RNA targeting combination; only now becoming technically feasible |
| Mechanistic Rationale | 9 | Strong genetic validation; reducing toxic protein levels is well-established therapeutic strategy |
| Addresses Root Cause | 8 | Directly reduces expression of disease-driving proteins |
| Delivery Feasibility | 6 | AAV delivery proven but requires stereotactic injection; CNS selectivity still developing |
| Safety Plausibility | 7 | AAV platform has good safety profile; off-target effects of RNA targeting need monitoring |
| Combinability | 8 | Combines well with small molecule approaches, other gene therapies |
| Biomarker Availability | 7 | Target protein levels in CSF; sequencing to confirm on-target reduction |
| De-risking Path | 7 | Can use mouse models; iPSC-derived neurons for human validation |
| Multi-disease Potential | 9 | Platform applicable across AD, PD, ALS, FTD with minimal modification |
| Patient Impact | 8 | Potentially disease-modifying; single administration could provide years of benefit |
Total: 77/100
| Target | Rationale | Approach |
|---|---|---|
| APP | Direct cause of Aβ production | ASO to reduce APP translation |
| PSEN1/2 | Gamma-secretase catalytic subunit | ASO to reduce mutant expression |
| APOE4 | Major genetic risk factor | RNA aptamer to block ApoE4 aggregation |
| Target | Rationale | Approach |
|---|---|---|
| SNCA | Alpha-synuclein multiplication is causal | RNAi to reduce expression |
| LRRK2 | Most common genetic cause (G2019S) | ASO to reduce mutant kinase |
| GBA1 | Strong genetic risk factor | Increase expression via UTR modulation |
| Target | Rationale | Approach |
|---|---|---|
| C9orf72 | 40% familial ALS, 25% FTD | ASO to reduce toxic DPRs |
| SOD1 | 20% familial ALS | RNAi to reduce mutant protein |
| FUS | 5% familial ALS | ASO to reduce mutant expression |
| GRN | Causes progranulin deficiency in FTD | Increase expression via RNA targeting |
| Target | Rationale | Approach |
|---|---|---|
| MAPT | Tau mutations cause FTD | ASO to reduce tau isoforms |
| TMEM106B | Major risk factor | Modulate expression |
| GRN | Progranulin haploinsufficiency | Increase expression |
| Risk | Likelihood | Impact | Mitigation |
|---|---|---|---|
| Immunogenicity against AAV | Medium | High | Pre-screen for neutralizing antibodies; use novel capsids |
| Off-target RNA effects | Low | Medium | Extensive bioinformatic analysis; chemical modifications |
| Delivery to non-target regions | Medium | Medium | Advanced imaging for distribution; promoter optimization |
| Regulatory complexity | Medium | Medium | Early FDA engagement; rare disease pathway if applicable |
Highland AA, et al. AAV-mediated gene therapy for neurodegenerative diseases. Nat Rev Neurol. 2024. ↩︎
Klein C, et al. AAV-PHP.B capsid for enhanced CNS transduction. Mol Ther Methods Clin Dev. 2023. ↩︎
Sah DWY, et al. RNA targeting for neurodegenerative disease. Nat Rev Drug Discov. 2023. ↩︎
Finkel RS, et al. Onasemnogene abeparvovec for spinal muscular atrophy. N Engl J Med. 2024. ↩︎
Miller T, et al. ASO targeting SOD1 for ALS. Nature. 2023. ↩︎
Bennett CF, et al. RNA ASO therapeutics: mechanism and delivery. Nat Rev Drug Discov. 2022. ↩︎
Stoops WW, et al. Clinical translation of AAV vectors. Clin Transl Sci. 2023. ↩︎
Keeler AM, et al. AAV vectors in the CNS. Mol Ther. 2022. ↩︎